Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1986-3-11
|
pubmed:abstractText |
Fifty-nine patients with chronic generalized tonic-clonic or partial seizures refractory to the maximally tolerated daily dosage of single-drug therapy with carbamazepine, phenytoin, phenobarbital, or primidone subsequently received single-drug therapy with another one of these primary anticonvulsant drugs. Alternative single-drug therapy resulted in complete seizure control or more than 75% seizure reduction for 18 patients (31%). Side effects disappeared in 16 patients (27%). Patients with a good therapeutic response often had epilepsy of recent onset. Alternative single-drug therapy is beneficial for chronic refractory epilepsy and should be considered before a second drug is permanently added.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticonvulsants,
http://linkedlifedata.com/resource/pubmed/chemical/Carbamazepine,
http://linkedlifedata.com/resource/pubmed/chemical/Phenobarbital,
http://linkedlifedata.com/resource/pubmed/chemical/Phenytoin,
http://linkedlifedata.com/resource/pubmed/chemical/Primidone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0364-5134
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
85-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3947041-Adult,
pubmed-meshheading:3947041-Anticonvulsants,
pubmed-meshheading:3947041-Carbamazepine,
pubmed-meshheading:3947041-Chronic Disease,
pubmed-meshheading:3947041-Epilepsy,
pubmed-meshheading:3947041-Humans,
pubmed-meshheading:3947041-Phenobarbital,
pubmed-meshheading:3947041-Phenytoin,
pubmed-meshheading:3947041-Primidone
|
pubmed:year |
1986
|
pubmed:articleTitle |
Alternative single anticonvulsant drug therapy for refractory epilepsy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|